Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling

被引：15

作者：

Beland, FA ^{[1
]}

Churchwell, MI

Hewer, A

Phillips, DH

da Costa, GG

Marques, MM

机构：

[1] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA

[2] Inst Canc Res, Sutton SM2 5NG, Surrey, England

[3] Univ Tecn Lisboa, Ctr Quim Estrutural, Inst Super Tecn, P-104900 Lisbon, Portugal

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2004年 / 320卷 / 02期

关键词：

tamoxifen; P-32-postlabeling; HPLC; electrospray ionization tandem mass spectrometry; DNA adducts; endometrial cancer;

D O I：

10.1016/j.bbrc.2004.05.168

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The nonsteroidal antiestrogen tamoxifen increases the risk of endometrial cancer; however, the mechanism for the induction of these tumors is not known. Recently, Sharma et a]. [Biochem. Biophys. Res. Commun. 307 (2003) 157], using high performance liquid chromatography (HPLC) with online postcolumn photochemical activation and fluorescence detection, reported the presence of (E)-alpha-(deoxyguanosin-N-2-yl)tamoxifen in DNA from human endometrial explants incubated with tamoxifen. Inasmuch as the methodology used by these investigators does not allow unambiguous characterization of tamoxifen-DNA adducts, we have used two additional techniques (HPLC coupled with electrospray ionization tandem mass spectrometry and P-32-postlabeling analyses) to assay for the presence of tamoxifen-DNA adducts in the human endometrial explant DNA. Tamoxifen-DNA adducts were not detected by either method. (C) 2004 Elsevier Inc. All rights reserved.

引用

页码：297 / 302

页数：6

共 24 条

[1]

BELAND FA, 2004, IN PRESS J NATL CANC

[2] Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen? [J].

Bergh, J .

LANCET, 2003, 362 (9379) :183-184

[3] Correspondence regarding M. Sharma et al., "Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture" [J].

Brown, K ;

Carmichael, PL .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 310 (04) :1039-1039

[4]

Carmichael PL, 1996, CANCER RES, V56, P1475

[5] Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium [J].

Carmichael, PL ;

Sardar, S ;

Crooks, N ;

Neven, P ;

Van Hoof, I ;

Ugwumadu, A ;

Bourne, T ;

Tomas, E ;

Hellberg, P ;

Hewer, AJ ;

Phillips, DH .

CARCINOGENESIS, 1999, 20 (02) :339-342

[6]

Clarke M, 1998, LANCET, V351, P1451

[7]

Cuzick J, 2002, LANCET, V360, P817

[8] Overview of the main outcomes in breast-cancer prevention trials [J].

Cuzick, J ;

Powles, T ;

Veronesi, U ;

Forbes, J ;

Edwards, R ;

Ashley, S ;

Boyle, P .

LANCET, 2003, 361 (9354) :296-300

[9] Synthesis and investigation of α-hydroxy-N,N-didesmethyltamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen [J].

da Costa, GG ;

Marques, MM ;

Freeman, JP ;

Beland, FA .

CHEMICAL RESEARCH IN TOXICOLOGY, 2003, 16 (09) :1090-1098

[10] Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry [J].

da Costa, GG ;

Marques, MM ;

Beland, FA ;

Freeman, JP ;

Churchwell, MI ;

Doerge, DR .

CHEMICAL RESEARCH IN TOXICOLOGY, 2003, 16 (03) :357-366

← 1 2 3 →